Uğur Şahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)

BioN­Tech nabs up to $90M for mpox vac­cine as it be­gins PhI/II tri­al be­hind Mod­er­na's lead

Build­ing on its in­fec­tious dis­ease work in Covid-19, malar­ia and tu­ber­cu­lo­sis, BioN­Tech is now rolling out a Phase I/II test of a jab to pro­tect against the mpox virus, which caused in­ter­na­tion­al con­cern in the sum­mer of 2022 but has since waned.

Like its Covid-19 vac­cine coun­ter­part Mod­er­na, the Ger­man biotech is hop­ing to cre­ate an mR­NA-based vac­cine for mpox, which can lead to ir­ri­ta­ble skin le­sions, rash­es and painful swelling of the lymph nodes.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.